Latent cytomegalovirus infection does not influence long-term disease outcomes in inflammatory bowel disease, but is associated with later onset of disease

References list

• Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785–1794.
   PubMed Web of Science ®Google Scholar
• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet (London). 2017;389(10080):1756–1770.
   PubMed Web of Science ®Google Scholar
• Torres J, Mehandru S, Colombel J-F, et al. Crohn’s disease. Lancet (London). 2017;389(10080):1741–1755.
   PubMed Web of Science ®Google Scholar
• van der Sloot KWJ, Amini M, Peters V, et al. Inflammatory bowel diseases: review of known environmental protective and risk factors involved. Inflamm Bowel Dis. 2017;23(9):1499–1509.
   PubMed Web of Science ®Google Scholar
• Cascio A, Iaria C, Ruggeri P, et al. Cytomegalovirus pneumonia in patients with inflammatory bowel disease: a systematic review. Int J Infect Dis. 2012;16(7):e474–e479.
   PubMed Web of Science ®Google Scholar
• van Langenberg DR, Morrison G, Foley A, et al. Cytomegalovirus disease, haemophagocytic syndrome, immunosuppression in patients with IBD: “a cocktail best avoided, not stirred”. J Crohns Colitis. 2011;5(5):469–472.
   PubMed Web of Science ®Google Scholar
• Rowan C, Judge C, Cannon MD, et al. Severe symptomatic primary CMV infection in inflammatory bowel disease patients with low population seroprevalence. Gastroenterol Res Pract. 2018;2018:1029401.
   PubMed Web of Science ®Google Scholar
• Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010;20(4):202–213.
   PubMed Web of Science ®Google Scholar
• Clos-Parals A, Rodríguez-Martínez P, Cañete F, et al. Prognostic value of the burden of cytomegalovirus colonic reactivation evaluated by immunohistochemical staining in patients with active ulcerative colitis. J Crohns Colitis. 2019;13(3):385–388.
   PubMed Web of Science ®Google Scholar
• Garrido E, Carrera E, Manzano R, et al. Clinical significance of cytomegalovirus infection in patients with inflammatory bowel disease. World J Gastroenterol. 2013;19(1):17–25.
   PubMed Web of Science ®Google Scholar
• Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis. 2010;16(9):1620–1627.
   PubMed Web of Science ®Google Scholar
• Slifkin M, Doron S, Snydman DR. Viral prophylaxis in organ transplant patients. Drugs. 2004;64(24):2763–2792.
   PubMed Web of Science ®Google Scholar
• Kaplan JE, Benson C, Holmes KK, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1–207.
   Google Scholar
• Gianella S, Letendre S. Cytomegalovirus and HIV: a dangerous Pas de Deux. J Infect Dis. 2016;214(Suppl 2):S67–S74.
   PubMed Web of Science ®Google Scholar
• Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: The National Health and Nutrition Examination Surveys, 1988–2004. Clin Infect Dis. 2010;50(11):1439–1447.
   PubMed Web of Science ®Google Scholar
• Römkens TEH, Bulte GJ, Nissen LHC, et al. Cytomegalovirus in inflammatory bowel disease: a systematic review. World J Gastroenterol. 2016;22(3):1321–1330.
   PubMed Web of Science ®Google Scholar
• Imhann F, Van der Velde KJ, Barbieri R, et al. The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1. BMC Gastroenterol. 2019;19(1):5.
   PubMedGoogle Scholar
• Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 (Suppl A):5A–36A.
   PubMed Web of Science ®Google Scholar
• Lagrou K, Bodeus M, Van Ranst M, et al. Evaluation of the new architect cytomegalovirus immunoglobulin M (IgM), IgG, and IgG avidity assays. J Clin Microbiol. 2009;47(6):1695–1699.
   PubMed Web of Science ®Google Scholar
• Korndewal MJ, Mollema L, Tcherniaeva I, et al. Cytomegalovirus infection in the Netherlands: seroprevalence, risk factors, and implications. J Clin Virol. 2015;63:53–58.
   PubMed Web of Science ®Google Scholar
• Dowd JB, Aiello AE, Alley DE. Socioeconomic disparities in the seroprevalence of cytomegalovirus infection in the U.S. population: NHANES III. Epidemiol Infect. 2009;137(1):58–65.
   Google Scholar
• Yi F, Zhao J, Luckheeram RV, et al. The prevalence and risk factors of cytomegalovirus infection in inflammatory bowel disease in Wuhan, Central China. Virol J. 2013;10(1):43.
   PubMedGoogle Scholar
• Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol. 2006;101(12):2857–2865.
   PubMed Web of Science ®Google Scholar
• Nakase H, Matsumura K, Yoshino T, et al. Systematic review: cytomegalovirus infection in inflammatory bowel disease. J Gastroenterol. 2008;43(10):735–740.
   PubMed Web of Science ®Google Scholar
• Hommes DW, Sterringa G, van Deventer SJH, et al. The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis. 2004;10(3):245–250.
   PubMed Web of Science ®Google Scholar
• Lavagna A, Bergallo M, Daperno M, et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis. 2007;13(7):896–902.
   PubMed Web of Science ®Google Scholar
• Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8(6):443–468.
   PubMed Web of Science ®Google Scholar